CompletedPhase 1NCT00005845
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
Studying Acquired idiopathic sideroblastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Razelle Kurzrock, M.DM.D. Anderson Cancer Center
- Intervention
- tipifarnib(drug)
- Enrollment
- 65 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2002
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005845 on ClinicalTrials.govOther trials for Acquired idiopathic sideroblastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06270771OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot StudySunnybrook Health Sciences Centre
- RECRUITINGNANCT04869683Biocollection in MyeloDysplastic Syndrome (P-MDS)University Hospital, Brest
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT00392353Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaNational Cancer Institute (NCI)
See all trials for Acquired idiopathic sideroblastic anemia →